With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.151038-94-7,6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide 2,2,2-trifluoroacetate,as a common compound, the synthetic route is as follows.
[00246] Acetate 4-(1 -(2-(6-(2,5-dioxo-2H-pyrrol-1 (5H)- yl)hexanoyl)hydrazono)ethyl)benzoate oxaliplatin was synthesized using acetoxyoxalplatin(4-acetylphenyl)carboxylate (328 mg, 0.529 mmol, 1 .00 equiv) that was dissolved in DMF (0.05 M, 10 mL) and treated with 6-(2,5-dioxo-2,5- dihydro-1 H-pyrrol-1 -yl)hexanehydrazide TFA salt (359 mg, 1 .05 mmol, 2.00 equiv). The reaction mixture was stirred at room temperature for 16 hours. MTBE was added to the reaction mixture until a gum was formed and the solvent was decanted. To the gummy residue was added more MTBE and the mixture was incubated in an ultrasonic bath until the gum turned into a yellow solid. The solid was filtered and rinsed with MTBE to afford compound 15(126 mg, 29%, 93.2% pure); 1 H NMR (500 MHz, DMF-d7) delta 10.50 (s, 0.4H), 10.42 (s, 0.6H), 8.95-8.44 (m, 4H), 7.92-7.88 (m, 4H), 7.03 (s, 0.8H), 7.02 (s, 1 .2H), 3.62-3.35 (m, 6H), 2.46-2.33 (m, 5H), 1 .98 (s, 3H), 1 .78-1 .50 (m, 8H), 1 .43-1 .22 (m, 4H); HPLC-MS 93.2%, m/z for C29H37N501 1 Pt [(M+H)+] = 828.3, 151038-94-7
As the paragraph descriping shows that 151038-94-7 is playing an increasingly important role.
Reference£º
Patent; BLEND THERAPEUTICS, INC.; MOREAU, Benoit; BILODEAU, Mark T.; WHALEN, Kerry; MEETZE, Kristan; SINGH, Sukhjeet; WOOSTER, Richard; LEMELIN, Charles-Andre; (139 pag.)WO2015/200250; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem